Intensity-Modulated Radiation Therapy: Supportive Data for Prostate Cancer

Seminars in Radiation Oncology

Volumn 18, Issue 1, 2008, Pages 48-57

  Cahlon, Oren ^a   Hunt, Margie ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; NEPHROTOXICITY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; TREATMENT PLANNING;

HUMANS; LYMPHATIC IRRADIATION; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 36849079824     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.09.007     Document Type: Article

References (86)

1. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
2. Hanks G.E., Hanlon A.L., Epstein B., et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
3. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
4. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
5. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
6. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
7. Eade T.N., Hanlon A.L., Horwitz E.M., et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 682-689
8. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1074-1081
9. Zelefsky M.J., Hunt M.A., Fuks Z., et al. Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66 suppl 1 (2006) S9 (abstr)
10. Chism D.B., Horwitz E.M., Hanlon A.L., et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 55 (2003) 71-77
11. Lawton C., Won M., Pilepich M., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 (1991) 935-939
12. Smit W.W.G., Helle P.P.A., van Putten W.W.L., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 (1990) 23-29
13. Ling C.C., Burman C., Chui C.S., et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Physs 35 (1996) 721-730
14. De Meerleer G.O., Vakaet L.A., De Gersem W.R., et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int J Radiat Oncol Biol Phys 47 (2000) 639-648
15. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
16. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
17. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 10 (2006) 82-86
18. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 160-166
19. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 49 (2001) 705-712
20. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
21. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
22. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
23. Cahlon O., Zelefsky M.J., Shippy A., et al. Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes. Int J Radiat Oncol Biol Phys 66 suppl 1 (2006) S33 (abstr)
24. Pisansky T.M. External-beam radiotherapy for localized prostate cancer. N Engl J Med 355 (2006) 1583-1591
25. Kupelian P.A., Buchsbaum J.C., Reddy C.A., et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason <= 6, and pretreatment prostate-specific antigen <= 10). Int J Radiat Oncol Biol Phys 50 (2001) 621-625
26. Pollack A., Hanlon A.L., Horwitz E.M., et al. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol 171 (2004) 1132-1136
27. Fuks Z., Leibel S.A., Wallner K.E., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21 (1991) 537-547
28. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1074-1081
29. Valicenti R., Lu J., Pilepich M., et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18 (2000) 2740-2746
30. Hanks G.E., Teshima T., and Pajak T.F. 20 years of progress in radiation oncology: Prostate cancer. Semin Radiat Oncol 7 (1997) 114-120
31. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 2460-2468
32. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
33. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
34. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
35. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
36. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
37. Dearnaley D.P., Sydes M.R., Langley R.E., et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 (2007) 31-41
38. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1056-1065
39. Penson D.F., and Litwin M.S. Quality of life after treatment for prostate cancer. Curr Urol Rep 4 (2003) 185-195
40. Litwin M.S., Gore J.L., Kwan L., et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109 (2007) 2239-2247
41. van Tol-Geerdink J.J., Stalmeier P.F.M., van Lin E.N.J.T., et al. Do patients with localized prostate cancer treatment really want more aggressive treatment?. J Clin Oncol 24 (2006) 4581-4586
42. Lips I., Dehnad H., Kruger A.B., et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69 (2007) 656-661
43. Namiki S.S., Ishidoya S.S., Tochigi T.T., et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy. Jap J Clin Oncol 36 (2006) 224-230
44. Speight J.L., and Roach III M. Advances in the treatment of localized Prostate Cancer: The role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 25 (2007) 987-995
45. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
46. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
47. Liu Y.-M., Shiau C.-Y., Lee M.-L., et al. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1113-1123
48. Su A.W., and Jani A. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol Cancer Clin Trials 30 (2007) 215-219
49. Shih H.A., Harisinghani M., Zietman A.L., et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63 (2005) 1262-1269
50. Wang-Chesebro A., Xia P., Coleman J., et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 654-662
51. Bostrom P.J., and Soloway M.S. Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk?. Eur Urol 52 (2007) 973-982
52. Brenner D.J., Hall E.J., and Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88 (2000) 398-406
53. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1-7
54. Hall E.J., and Wuu C.S. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56 (2003) 83-88
55. Kry S.F., Salehpour M., Followill D.S., et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1195-1203
56. Schneider U., Lomax A., Besserer J., et al. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 892-897
57. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
58. Zelefsky M.J., Fuks Z., Leibel S.A., et al. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 12 (2002) 229-237
59. Burman C., Chui C.S., Kutcher G., et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39 (1997) 863-873
60. Ma L., Yu C.X., Earl M., et al. Optimized intensity-modulated arc therapy for prostate cancer treatment. Int J Cancer 96 (2001) 379-384
61. Yu C.X., Li X.A., Ma L., et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys 53 (2002) 453-463
62. Curran B. Where goest the peacock?. Med Dosim 26 (2001) 3-9
63. Grigorov G., Kron T., Wong E., et al. Optimization of helical tomotherapy treatment plans for prostate cancer. Phys Med Biol 48 (2003) 1933-1943
64. Rodrigues G., Yartsev S., Chen J., et al. A comparison of prostate IMRT and helical tomotherapy class solutions. Radiother Oncol 80 (2006) 374-377
65. Pirzkall A., Carol M.P., Pickett B., et al. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys 53 (2002) 434-442
66. Price R.A., Hanks G.E., McNeeley S.W., et al. Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method. Int J Radiat Oncol Biol Phys 53 (2002) 236-243
67. Aoyama H., Westerly D.C., Mackie T.R., et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys 64 (2006) 962-967
68. Bortfeld T. Optimized planning using physical objectives and constraints. Semin Radiat Oncol 9 (1999) 20-34
69. Verhey L.J. Issues in optimization for planning of intensity-modulated radiation therapy. Semin Radiat Oncol 12 (2002) 210-218
70. Spirou S.V., and Chui C.S. A gradient inverse planning algorithm with dose-volume constraints. Med Phys 25 (1998) 321-333
71. Spirou S.V., and Chui C.S. Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators. Med Phys 21 (1994) 1031-1041
72. Skwarchuk M.W., Jackson A., Zelefsky M., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer I: Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
73. Algan O., Hanks G.E., and Shaer A.H. Localization of the prostatic apex for radiation treatment planning. Int J Radiat Oncol Biol Phys 33 (1995) 925-930
74. Milosevic M., Voruganti S., Blend R., et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: Comparison to computed tomography (CT) and urethrography. Radiother Oncol 47 (1998) 277-284
75. Roach M.R., Faillace-Akazawa P., Malfatti C., et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35 (1996) 1011-1018
76. Rasch C., Barillot I., Remeijer P., et al. Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys 43 (1999) 57-66
77. Chen L., Price Jr. R.A., Nguyen T.B., et al. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. Phys Med Biol 49 (2004) 5157-5170
78. Zelefsky M., Crean D., Mageras G.S., et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50 (1999) 225-234
79. Kuban D.A., Dong L., Cheung R., et al. Ultrasound-based localization. Semin Radiat Oncol 15 (2005) 180-191
80. Balter J.M., Sandler H.M., Lam K., et al. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 31 (1995) 113-118
81. Crook J.M., Raymond Y., Salhani D., et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37 (1995) 35-42
82. Sandler H.M., Bree R.L., McLaughlin P.W., et al. Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys 27 (1993) 915-919
83. Langen K.M., Zhang Y., Andrews R.D., et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 62 (2005) 1517-1524
84. Létourneau D., Martinez A.A., Lockman D., et al. Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients. Int J Radiat Oncol Biol Phys 62 (2005) 1239-1246
85. Moseley D.J., White E.A., Wiltshire K.L., et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67 (2007) 942-953
86. Martin JM, Rosewall T, Bayley A, et al: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (in press)